Preclinical Anticancer Efficacy Studies on IBAL Formulations

Preliminary Evaluation of ION-ZC1 as a Potential Anticancer Agent In Vitro

Completed in 2018 by Brooklyn College and The City University of New York, USA

The foundation of the Anticancer Efficacy Studies for ION-ZC1, a core active in the IBAL platform, was laid with its in vitro testing on multiple human cancer cell lines. The study revealed that the ION-ZC1 solution demonstrates cytotoxicity across various cancer models, while maintaining selectivity and low toxicity to healthy cells.

ION-ZC1 exhibited strong inhibitory effects on:

• Renal carcinoma (Caki-1) — IC50 36.12 ± 1.00 μM
• Triple-negative breast cancer (MDA-MB-231)
• Melanoma (A375) — IC50 95.20 ± 1.01 μM

Significantly, the cytotoxicity toward healthy control cells (IMR-90) was notably lower, with an IC50 of 142.6 ± 6.65 μM, confirming its selective action against malignant cells. The compound was also shown to induce apoptotic death in 92% of the renal carcinoma cells at the stated concentration, emphasizing its mechanism of action through programmed cell death, rather than general toxicity.

These results established ION-ZC1 as a selective anticancer agent, making it a viable candidate for further topical and systemic application studies.

ION-ZC1 Topical Cream Anti-Tumor Efficacy Study Using Syngeneic Mouse Melanoma Model

Completed in 2017 by the University of Debrecen, Hungary

In this stage of the Anticancer Efficacy Studies, researchers tested a topical cream formulation containing 17% ION-ZC1 in a syngeneic mouse melanoma model (B16F0 in C57BL/6J). The study involved 30 mice and compared ION-ZC1 with Imiquimod 5% (ALDARA), a known topical immunomodulator used in some skin cancers.

The findings were compelling:

• ION-ZC1 Topical Cream significantly inhibited tumor growth.
• Tumor volume was reduced more effectively than with Imiquimod.
• Survival time was extended in the ION-ZC1 group.

This suggests that the topical route using the IBAL formulation can achieve meaningful antitumor effects, especially for cutaneous or dermal malignancies such as melanoma, basal cell carcinoma, or pre-cancerous skin lesions.

ION-ZC1 Intravenous Anti-Tumor Efficacy Study in Mouse Xenograft Model

Completed in 2016 by the University of Debrecen, Hungary

A third major study within the Anticancer Efficacy Studies evaluated the systemic effects of ION-ZC1 via intravenous (IV) injection using a subcutaneous B16 mouse melanoma model. The 14-day observation study concluded with key findings from histopathological analyses:

• Massive tumor necrosis was observed in ION-ZC1-treated mice.
• Vascularization within tumors was significantly reduced, suggesting anti-angiogenic activity.
• Spleen enlargement (2–3×) in treated mice indicated a heightened immune response, possibly due to immune system activation against tumor cells.

Importantly, no adverse safety signals or organ damage were observed in treated animals, confirming that ION-ZC1 is well tolerated systemically. This is particularly relevant as it opens a path for parenteral drug development in oncological settings where topical delivery is not feasible.

Significance of These Anticancer Efficacy Studies

Together, these preclinical Anticancer Efficacy Studies provide a comprehensive look at the multi-modal therapeutic potential of ION-ZC1, both topically and systemically. Key takeaways include:

• Selective cytotoxicity toward cancer cells, sparing healthy tissues
• Apoptosis induction and tumor necrosis
• Suppression of angiogenesis, limiting tumor blood supply
• Immunological activation, suggesting potential for combination with immunotherapies

The IBAL platform enhances bioavailability through cationic coordination (zinc, copper, magnesium, sulfur, hydrogen), which facilitates deep tissue penetration and controlled redox activity, supporting both direct tumor suppression and host immune modulation.

These studies support ongoing discussions to transition ION-ZC1 from preclinical research to Investigational New Drug (IND) submission, particularly for melanoma, renal carcinoma, and triple-negative breast cancer.

Future Research and Clinical Prospects

Based on the promising outcomes of these Anticancer Efficacy Studies, future work will likely focus on:

• Expanded dosing studies and toxicity evaluation in larger animal models
• Exploration of combination protocols with known agents (e.g., checkpoint inhibitors)
• Formulation refinement for human-use topical and injectable drug products
• Clinical Phase 1 planning, subject to regulatory feedback

Given the growing demand for non-cytotoxic and immune-responsive cancer therapies, ION-ZC1 represents a next-generation oncology asset developed through a biotechnology-driven, redox-based approach.